Ripasudil

Drug Profile

Ripasudil

Alternative Names: Glanatec; K-115; K-115-R; Ripasudil hydrocholoride hydrate

Latest Information Update: 16 Nov 2016

Price : $50

At a glance

  • Originator D. Western Therapeutics Institute
  • Developer Kowa Pharmaceutical
  • Class Azepines; Eye disorder therapies; Fluorine compounds; Isoquinolines; Small molecules; Sulfonamides
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension
  • Phase II Diabetic retinopathy

Most Recent Events

  • 02 Dec 2014 Launched for Glaucoma (Combination therapy, Monotherapy) in Japan (Ophthalmic)
  • 02 Dec 2014 Launched for Ocular hypertension (Combination therapy, Monotherapy) in Japan (Ophthalmic)
  • 26 Sep 2014 Registered for Glaucoma (Monotherapy & Combination therapy) in Japan (Ophthalmic) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top